![](https://www.lachmanconsultants.com/wp-content/themes/lac/wp-content/uploads/2023/02/missing-thumbnail.jpg)
Long Awaited Advair Bioequivalence Draft Guidance Is Published
On September 9, 2013, the FDA published a draft guidance designed to provide current agency thinking on the methods and testing necessary to establish bioequivalence between the reference listed drug (RLD) and the generic powder for inhalation.